CRDF
Cardiff Oncology·NASDAQ
--
--(--)
--
--(--)
4.87 / 10
Netural
Analyst sentiment is overwhelmingly bullish with a Strong Buy rating from HC Wainwright & Co., but historical win rates are only 25%. Fund-flow analysis shows a 7.72/10 score with positive liquidity trends, although current block and medium inflows are negative. This combination suggests cautious optimism despite short-term outflows.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionHC Wainwright & Co.
Times predicted4
Historical Win Rate25.0%
What is the analyst consensus for CRDF?
- CRDF holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.87/10 (Netural).
